A New Dipeptide H-MGL Partially Ameliorating Memory Impairment in an STZ-induced Alzheimer Model in Male Rats

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer disease (AD) involves cognitive decline, amyloid plaques, and neurofibrillary tangles.
• Neurotrophic factors are crucial for AD treatment but have limitations.
• Novel dipeptides offer a promising alternative with potentially fewer side effects.

Purpose of the Study:

• To evaluate the efficacy of H-MGL, a new neurotrophin-mimetic dipeptide, in an STZ-induced rat model of Alzheimer disease.
• To assess H-MGL's ability to alleviate memory impairment and cognitive deficits.

Main Methods:

• An Alzheimer model was induced in rats using streptozotocin (STZ).
• Rats were divided into four groups: Sham, STZ, and STZ treated with H-MGL (1 mg/kg or 2 mg/kg).
• H-MGL was administered daily for 14 days post-STZ injection, followed by Morris water maze testing.

Main Results:

• STZ administration significantly increased escape latency and distance traveled, indicating cognitive impairment.
• A 1 mg/kg dose of H-MGL showed no significant improvement compared to STZ.
• A 2 mg/kg dose of H-MGL significantly reduced latency and frequency of platform crossings, improving spatial memory.

Conclusions:

• H-MGL, particularly at 2 mg/kg, partially ameliorates cognitive impairment in an STZ-induced AD rat model.
• This dipeptide demonstrates potential for treating cognitive deficits in Alzheimer disease with possibly fewer side effects.
• H-MGL warrants further investigation as a therapeutic agent for AD progression.